Life-extension therapy: Glimepride (Trade name: Amaryl), a sulphonylurea antidiabetic drug, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 4/January/2017, 5.49 pm

Vitamin-based Cardiac rejuvenation therapy: Ascorbic acid suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy and heart failure via up regulation of its target gene, 4/January/2017, 3.20 pm
January 4, 2017
Natural product-derived combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: Bergapten (5-methoxypsoralen), a natural psoralen derivative present in many fruits and vegetables, decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 4/January/2017, 10.01 pm
January 4, 2017
Show all

What they say?

A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 ) by Prof Dominic J. Withers, Dr. Selman C and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports, for the first time, that:  Life-extension therapy: Glimepride, a sulphonylurea antidiabetic drug, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span


Research findings to Therapeutic opportunity: 

This study reveals, for the first time, the known anti-diabetic drug Glimepride‘s unknown function as a lifespan-promoter. 

Glimepride, by  increasing  the expression of its target gene, it may suppress Ribosomal protein S6 kinase 1 (p70S6 Kinase) expression. Thereby, it may promote: (1) resistance to bone, immune, and motor dysfunction; (2) insulin sensitivity; and (3) longevity (fig. 1).   

glimepride-may-extend-mamalian-lifespan-by-suppressing-p70s6-kinase

Fig 1. The antidiabetic drug Glimepride may function as a longevity promoter. Glimepride, by suppressing the expression of p70 S6 Kinase, it may extend the lifespan.

price-100[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing Glimepride either alone or or in combination with any of the known longevity-promoting compound(s) may be used to extend the lifespan of an individual (fig. 1).


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed Information: How Glimepride decreases the expression of p70 S6 Kinase and extends mammalian life span?

# Research cooperation

Amount: $100 #


References:

CitationBoominathan, L.,  Life-extension therapy: Glimepride (Trade name: Amaryl), a sulphonylurea antidiabetic drug, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 4/January/2017, 5.49 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.